Elevance Health (ELV) Stock May Be Undervalued On Reaffirmed 2026 Guidance

September 19, 2026 - 19:03

Elevance Health has had a strong run over the past year, and the stock is now trading with recent news about its earnings outlook fresh in investors' minds. The core question is whether the current share price is warranted by the healthcare insurer's ability to keep converting its profit story into sustainable earnings per share.

The stock has gained 33.6% over the past 12 months, which puts more weight on whether that move is supported by the underlying earnings power of the company. Management recently reaffirmed its guidance for 2026, a signal that it expects the business to keep growing even as the broader healthcare landscape shifts.

That reaffirmation matters because it gives investors a clearer view of how the company sees its own future. Insurers face pressure from rising medical costs, changing regulations, and shifting membership trends. Elevance has managed to navigate those challenges while keeping its profit targets intact.

If the 2026 guidance holds, the current valuation could look modest compared to where earnings are headed. The stock trades at a level that suggests the market is not fully pricing in that growth. For investors who believe the company can hit its targets, the shares may offer room to run. The risk, as always, is that costs or policy changes disrupt the plan. For now, the numbers suggest the stock is not expensive relative to its own outlook.